Skip to main content

Year: 2025

Tecan reports 2024 financial results, enhancing operational resilience amid challenging conditions

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports 2024 financial results, enhancing operational resilience amid challenging conditions Financial results for the full year 2024 – HighlightsSales of CHF 934.3 million (2023: CHF 1,074.4 million), down by -13.0% in Swiss francs and by -11.5% in local currencies; H2 sales decrease by -11.3% in local currencies Decline in sales mainly due to softness in the instrument business with biopharmaceutical companies globally and general market weakness in China Adjusted EBITDA of CHF 164.4 million (2023: CHF 220.6 million), adjusted EBITDA margin reached 17.6% (2023: 20.5%) Margins declined due to lower sales volume, but were partly offset by cost-reduction measures Adjusted net profit of CHF 103.1 million (2023: CHF 164.4 million), adjusted earnings...

Continue reading

Lantronix to Showcase Embedded Compute, Industrial IoT and Out-of-Band Solutions at Embedded Tech India Expo

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge Intelligence, today announced that it will showcase its leading-edge embedded compute, Industrial IoT (IIoT) and out-of-band management solutions at Embedded Tech India Expo, co-located with Convergence India Expo, being held March 19–21, 2025, in Bharat Mandapam, New Delhi, India. Lantronix will display at booth #C248 in Hall 3 (Embedded Compute section). “Our presence at the Embedded Tech India Expo reinforces our dedication to delivering cutting-edge solutions that support India’s evolving technology landscape and its rapidly growing sectors in Smart Cities, Enterprise and Transportation,” said Mathi Gurusamy, chief strategy officer at Lantronix. “A global technology...

Continue reading

Crown Point Announces Unaudited Financial and Operating Results for the Three Months and Year Ended December 31, 2024

CALGARY, Alberta, March 11, 2025 (GLOBE NEWSWIRE) — TSX-V: CWV: Crown Point Energy Inc. (“Crown Point”, the “Company” or “we”) today announced its unaudited financial and operating results for the three months and year ended December 31, 2024.   All dollar figures are expressed in United States dollars (“USD”) unless otherwise stated. In the following discussion, the three months and the year ended December 31, 2024 may be referred to as “Q4 2024” and “2024”, respectively. The comparative three months and year ended December 31, 2023 may be referred to as “Q4 2023” and “2023”, respectively. Q4 2024 SUMMARY During Q4 2024, the Company:Reported net cash used in operating activities of $1.5 million and funds flow provided by operating activities of $1.0 million; Earned $19.6 million of oil and natural gas sales revenue on total...

Continue reading

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of its common stock. All of the securities to be sold in the...

Continue reading

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

$250,000 top award goes to Matteo Paz in America’s longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Matteo Paz,18, of Pasadena, CA, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.’s oldest and most prestigious science and math competition for high school seniors. Now in its 84th year, the competition celebrates and rewards young innovators who are applying their Science, Technology, Engineering and Math (STEM) talent and leadership skills to push the boundaries of discovery and address today’s pressing challenges. Forty finalists, including Matteo, were honored this evening during an award ceremony at the National...

Continue reading

American Tungsten Corp. Responds to OTC Markets Request on Recent Promotional Activity

Vancouver, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE: TUNG) (OTCQB: DEMRF) (FSE: RK9) (“American Tungsten” or the “Company”) announces that it has received a request from OTC Markets Group Inc. (“OTC Markets”) to issue this statement regarding recent promotional activity concerning its common shares (the “Common Shares”) traded on the OTCQB Marketplace. Promotional Activity On March 4, 2025, OTC Markets informed the Company that it became aware of certain promotional activities concerning American Tungsten and its Common Shares, including the distribution of digital marketing materials by Emerging Markets Consulting, LLC (“EMC”). These materials discussed the Company’s projects, its business model, and the tungsten industry in general....

Continue reading

CORRECTION – Peyto Reports Strong Fourth Quarter and 2024 Annual Results

CALGARY, Alberta, March 11, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline on Tuesday, March 11, 2025, by Peyto Exploration & Development Corp., please note that in the table under Hedging, the following amounts in the line for “Natural Gas” should be “4.14” for 2025 and “4.02” for 2026, not “4.01” and “4.51”, respectively. The corrected release follows: Peyto Exploration & Development Corp. (“Peyto” or the “Company”) (TSX: PEY) is pleased to report operating and financial results for the fourth quarter and 2024 fiscal year, and senior management additions. Full Year and Q4 2024 Highlights:Delivered $199.0 million in funds from operations1,2 (“FFO”), or $1.00/diluted share, and $79.6 million of free funds...

Continue reading

Conifex Announces Fourth Quarter 2024 Results Conference Call

VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”) (TSX: CFF) announced today that it plans to release its fourth quarter 2024 results after market close on Wednesday, March 12, 2025. Conifex has scheduled a conference call at 8:00 AM Pacific time / 11:00 AM Eastern time the following morning March 13, 2025, to discuss its financial results. To participate in the call, please dial one of the following numbers: Toll-Free Access (Canada/US): 1-800-806-5484Local dial-in number: 416-340-9645Participant Pass Code: 1625539# A recording of the conference or transcript is available upon request. For further information, please contact: Trevor Pruden        Chief Financial Officer        investorrelations@conifex.com          About Conifex Timber Inc. Conifex and its subsidiaries’ primary...

Continue reading

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx’s Novel PluriFreeze™ Cryopreservation System HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx’s PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innovative...

Continue reading

Peyto Reports Strong Fourth Quarter and 2024 Annual Results

CALGARY, Alberta, March 11, 2025 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (“Peyto” or the “Company”) is pleased to report operating and financial results for the fourth quarter and 2024 fiscal year, and senior management additions. Full Year and Q4 2024 Highlights:Delivered $199.0 million in funds from operations1,2 (“FFO”), or $1.00/diluted share, and $79.6 million of free funds flow3 in the quarter. Annual FFO totaled $712.8 million or $3.62/diluted share, and annual free funds flow totaled $246.7 million. Annual capital expenditures4 of $457.6 million resulted in record production of 136 Mboe/d (720.7 MMcf/d gas, 15,708 bbl/d NGLs) in December, yielding a trailing 12-month capital efficiency5 of $9,700 boe/d. Peyto booked a record 6.0 Bcfe of Proved Developed Producing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.